Сравнение
Lixisenatide vs. Semaglutid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
320367-13-3
910463-68-2
Молекулярная масса
4858.5 g/mol
4113.6 g/mol
Период полувыведения
3 h
165 h
Последовательность
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerМеханизм действия
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
5
4
из них на людях
5
3
Зафиксированные эффекты
3
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
1
5
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Lixisenatide and Semaglutid?
- Lixisenatide is classified as "Метаболизм", while Semaglutid is classified as "Метаболизм". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lixisenatide or Semaglutid?
- The highest available evidence level is "РКИ на людях" for Lixisenatide and "РКИ на людях" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lixisenatide and Semaglutid in Germany and the United States?
- Германия: Lixisenatide — Рецептурный, Semaglutid — Рецептурный. США: Lixisenatide — Не одобрено, Semaglutid — Рецептурный. These are factual summaries with source and review date on the individual pages.